ALLO - Allogene Therapeutics, Inc.
2.26
-0.150 -6.637%
Share volume: 6,330,340
Last Updated: 03-27-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.04%
PREVIOUS CLOSE
CHG
CHG%
$2.41
-0.15
-0.06%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-13-2024 | 08-07-2024 | 11-07-2024 | 03-13-2025 | 05-13-2025 | 08-13-2025 | 11-06-2025 | 03-12-2026 | |
| Total revenue | 22.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 22.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| -100.00% | nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 69.526 M | 66.442 M | 61.046 M | 60.490 M | 65.191 M | 54.437 M | 44.901 M | 42.404 M | |
| Selling general and admin | 17.267 M | 16.087 M | 16.333 M | 15.518 M | 14.991 M | 14.281 M | 13.737 M | 13.772 M | |
| Research and development | 52.259 M | 50.355 M | 44.713 M | 44.972 M | 50.200 M | 40.156 M | 31.164 M | 28.632 M | |
| Total expenses | 69.526 M | 71.431 M | 71.774 M | 60.490 M | 65.191 M | 56.819 M | 44.901 M | 42.404 M | |
| 2.74% | 0.48% | -15.72% | 7.77% | -12.84% | -20.98% | -5.56% | |||
| Operating income | -69.504 M | -71.431 M | -71.774 M | -60.490 M | -65.191 M | -56.819 M | -44.901 M | -42.404 M | |
| Ebit | -65.000 M | -71.346 M | -72.898 M | -67.875 M | -65.099 M | -56.862 M | -44.982 M | -42.157 M | |
| Pretax income | -65.000 M | -66.358 M | -66.293 M | -59.496 M | -59.733 M | -50.943 M | -41.400 M | -38.810 M | |
| 2.09% | -0.10% | -10.25% | 0.40% | -14.72% | -18.73% | -6.26% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -65.000 M | -66.358 M | -66.293 M | -59.939 M | -59.733 M | -50.943 M | -41.400 M | -38.810 M | |
| -2.09% | 0.10% | 9.58% | 0.34% | 14.72% | 18.73% | 6.26% |